R
Rikke Olesen
Researcher at Aarhus University Hospital
Publications - 44
Citations - 2897
Rikke Olesen is an academic researcher from Aarhus University Hospital. The author has contributed to research in topics: Immune system & Panobinostat. The author has an hindex of 22, co-authored 37 publications receiving 2404 citations. Previous affiliations of Rikke Olesen include University of North Carolina at Chapel Hill & Aarhus University.
Papers
More filters
Journal ArticleDOI
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Thomas A Rasmussen,Martin Tolstrup,Christel R. Brinkmann,Rikke Olesen,Christian Erikstrup,Ajantha Solomon,Anni Winckelmann,Sarah Palmer,Charles A. Dinarello,Maria J. Buzon,Maria J. Buzon,Mathias Lichterfeld,Mathias Lichterfeld,Sharon R Lewin,Sharon R Lewin,Lars Østergaard,Ole S. Søgaard +16 more
TL;DR: Panobinostat effectively disrupts HIV latency in vivo and is a promising candidate for future combination clinical trials aimed at HIV eradication, however, panobinostats did not reduce the number of latently infected cells and this approach may need to be combined with others to significantly affect the latent HIV reservoir.
Journal ArticleDOI
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
Ole S. Søgaard,Mette E. Graversen,Steffen Leth,Rikke Olesen,Christel R. Brinkmann,Sara K. Nissen,Anne Sofie Høgh Kølbæk Kjær,Mariane H. Schleimann,Paul W. Denton,William J. Hey-Cunningham,Kersten K. Koelsch,Giuseppe Pantaleo,Kim Krogsgaard,Maja A. Sommerfelt,Rémi Fromentin,Nicolas Chomont,Thomas A Rasmussen,Lars Østergaard,Martin Tolstrup +18 more
TL;DR: A proof-of-concept phase Ib/IIa trial where 6 aviremic HIV-1 infected adults received intravenous 5 mg/m2 romidepsin (Celgene) once weekly for 3 weeks while maintaining ART demonstrates that significant reversal of HIV- 1 latency in vivo is possible without blunting T cell-mediated immune responses.
Journal ArticleDOI
Generation of HIV Latency in Humanized BLT Mice
Paul W. Denton,Rikke Olesen,Rikke Olesen,Shailesh K. Choudhary,Nancy M. Archin,Angela Wahl,Michael D. Swanson,Morgan Chateau,Tomonori Nochi,John F. Krisko,Rae Ann Spagnuolo,David M. Margolis,J. Victor Garcia +12 more
TL;DR: It is demonstrated that a combination of tenofovir, emtricitabine, and raltegravir effectively suppresses peripheral and systemic HIV replication in humanized BLT mice.
Journal ArticleDOI
DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans.
Rikke Olesen,Christian Wejse,Christian Wejse,Digna R. Velez,Cyrille Bisseye,Morten Sodemann,Peter Aaby,P Rabna,A Worwui,H Chapman,Mathurin Diatta,Richard A. Adegbola,Philip C. Hill,Lars Østergaard,Scott M. Williams,Giorgio Sirugo +15 more
TL;DR: The findings support previous data showing that VDR SNPs modulate the risk for TB in West Africans and suggest that variation within DC-SIGN and PTX3 also affect the disease outcome.
Journal ArticleDOI
Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans
Digna R. Velez,Christian Wejse,Christian Wejse,Martin E. Stryjewski,Eduardo Abbate,William Hulme,Jamie L. Myers,Rosa Estevan,Sara G. Patillo,Rikke Olesen,Alessandra Tacconelli,Giorgio Sirugo,John R. Gilbert,John R. Gilbert,Carol Dukes Hamilton,Carol Dukes Hamilton,William K. Scott,William K. Scott +17 more
TL;DR: Findings in three independent population samples indicate that variations in TLR2 and TLR9 might play important roles in determining susceptibility to TB.